Astel­las out­lines an­oth­er five-year plan; Bay­er's VC arm leaps in­to dig­i­tal health

Three years af­ter Astel­las un­veiled its last five-year plan, the Japan­ese phar­ma is un­veil­ing an­oth­er.

The new blue­print, an­nounced Wednes­day, is less sweep­ing or com­pre­hen­sive than the large R&D re-or­ga­ni­za­tion that Ken­ji Ya­sukawa in­stilled when he was first named CEO, but it of­fers new specifics and tar­gets.

The com­pa­ny set a goal of 30% prof­it by 2025. They’ll get there, they ex­plained, by ag­gres­sive­ly fil­ing and ex­pand­ing their Pfiz­er-part­nered prostate can­cer drug Xtan­di, which they ex­pect to now grow from a $4.2 bil­lion per year drug to a $5.5 bil­lion to $6.4 bil­lion drug. They al­so ex­pect ex­pand­ed rev­enues from their Seagen-part­nered ADC Pad­cev and they think their still-ex­per­i­men­tal women’s health drug fe­zo­line­tant will be­come a $2.75 bil­lion to $4.5 bil­lion drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER